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Cardiovascular disease is the primary cause of death among patients with breast cancer. However, the association of cardiovascular-disease risk factors (CVD-RFs) with long-term survival and cardiac events is not well studied.
Methods
We examined SWOG (formerly the Southwest Oncology Group) breast cancer trials from 1999 to 2011. We identified baseline diabetes, hypertension, hypercholesterolemia, and coronary artery disease by linking trial records to Medicare claims. The primary outcome was overall survival. Patients with both baseline and follow-up claims were examined for cardiac events. Cox regression was used to assess the association between CVD-RFs and outcomes.
Results
We identified 1,460 participants older than 66 years of age from five trials; 842 were eligible for survival outcomes analysis. At baseline, median age was 70 years, and median follow-up was 6 years. Hypertension (73%) and hypercholesterolemia (57%) were the most prevalent conditions; 87% of patients had one or more CVD-RF. There was no association between any of the individual CVD-RFs and overall survival except for hypercholesterolemia, which was associated with improved overall survival (hazard ratio [HR] , 0.73; 95% CI, 0.57 to 0.93; P = .01). With each additional CVD-RF, there was an increased risk of death (HR, 1.23; 95% CI, 1.08 to 1.40; P = .002), worse progressionfree survival (HR, 1.12; 95% CI, 1.00 to 1.25; P = .05), and marginally worse cancer-free survival (HR, 1.15; 95% CI, 0.99 to 1.34; P = .07). The relationship between baseline CVD-RFs and cardiac events was analyzed in 736 patients. A strong linear association between the number of CVD-RFs and cardiac event was observed (HR per CVD-RF, 1.41; 95% CI, 1.17 to 1.69; P , .001).
INTRODUCTION
During the past two decades, improvements in screening and treatment options in women with breast cancer (BC) have led to longer life spans and decreased rates of cancer-specific mortality; as a result, the risk of noncancer mortality has been increasing. 1 Cardiovascular disease increases the risk of noncancer mortality and is now the primary cause of death among patients with BC.
2, 3 Various risk factors are common to the development of both BC and cardiovascular disease, including diabetes, hypertension, hypercholesterolemia, and obesity. [4] [5] [6] Many of these comorbidities are also risk factors for worse survival among those diagnosed with BC. 7, 8 Patients with BC are at additional risk of developing incident cardiac conditions due to the cardiotoxic effects of various anticancer therapies, such as radiation, anthracycline chemotherapies, and trastuzumab, and the secondary effects of treatment such as increased frailty and deconditioning. [9] [10] [11] [12] However, the relationship between cardiovascular risk factors and long-term cardiac events among patients with BC is not well studied.
Author affiliations and support information (if applicable) appear at the end of this article.
The risk of incident BC and BC mortality increases with age, and although the relative hazard rates of BC mortality are decreasing overall, the decrease is less among elderly patients. 1, 13, 14 In addition, elderly women may experience significantly higher rates of cardiotoxic adverse effects from treatment than younger patients. 15 Data on mortality due to cardiovascular disease and rates of cardiac events among elderly patients are limited, however, especially because of under-representation of older patients in clinical trials. 16, 17 In this study, we assessed the relationship between cardiovasculardisease risk factors (CVD-RFs) and survival, as well as incidence of cardiac events among patients older than 66 years of age enrolled in a series of National Cancer Institute-sponsored adjuvant and advanced BC clinical treatment trials. CVD-RFs were identified using a novel linkage between the clinical trial records and Medicare claims data.
METHODS
We obtained data from SWOG, a member of the National Cancer Institute's Clinical Trials Network and Community Oncology Research Program. We examined the SWOG database to identify patients registered in phase II/III BC trials between 1999 and 2011, the period during which Medicare claims data were available for linkage to clinical records. We identified five eligible trials: S0012, S0221, S0226, S0307, and S0500 (Appendix Table A1 , online only).
18-21 Clinical records from these studies were linked to Medicare claims data according to Social Security number, sex, and date of birth. To be included in the analyses of whether baseline cardiovascular conditions were prognostic for survival outcomes, patients had to be at least 66 years of age at baseline and have at least 12 months of Medicare Parts A and B coverage immediately before baseline. To be included in the analyses of cardiac event outcomes, patients also needed at least 12 months of Medicare coverage at any point after registration to identify cardiac events after treatment initiation. In both cases, because health maintenance organization providers do not submit claims records to Centers for Medicare and Medicaid Services, patients must simultaneously have had no health maintenance organization coverage. Seventeen participants took part in more than one included trial; the trial with the earlier registration date was retained.
Various patient demographics, including age, sex, self-reported race and ethnicity, and baseline body mass index (BMI) were obtained from questionnaires administered at the time of enrollment. Comorbid conditions at baseline were identified using International Classification of Diseases (9th revision, clinical modification [ICD9]) codes from Medicare claims data and included diabetes (with and without chronic complications), hypertension, hypercholesterolemia, and coronary artery disease or ischemic heart disease (CAD; Appendix Table A2 , online only). Obesity, as a CVD-RF, was defined as BMI . 30 kg.m 2 using trial records. Postbaseline cardiac event outcomes were identified by ICD9, Healthcare Common Procedure Coding System, and Current Procedural Terminology surgical codes (Appendix Table A3 , online only). Conditions and events were identified as any hospital claim or two or more physician or outpatient claims at least 30 days apart. Survival outcomes data were obtained from SWOG clinical records. Medicare also provides dates of death, which were used to supplement SWOG data on death as a competing risk.
Statistical Methods
We used multivariable Cox regression to assess the impact of various baseline CVD-RFs on survival. The primary outcome was overall survival; secondary outcomes were progression-free survival and cancer-free survival. We defined overall survival as time from study registration to death due to any cause, progression-free survival as time from study registration to the development of progressive disease or death due to any cause, and cancer-free survival as time from study registration to death after in-study disease progression or any death that occurred within 180 days of registration. Analyses were stratified by study and treatment arm and adjusted for baseline age (66 to 70 v $ 70), race (black v nonblack), and baseline prognostic risk scores for cancer outcomes on the basis of prespecified study-specific stratification variables to account for prognostic risk across a panel of different studies (Appendix Table A4 , online only). Cox regression was performed separately for each cardiovascular condition, and an additional analysis was performed to assess the potential impact of having multiple concurrent cardiovascular risks. Secondary analyses were performed separately by study type (adjuvant [S0012, S0221, S0307] v advanced [S0226, S0500]).
We also investigated the impact of baseline CVD-RFs on the incidence of postbaseline cardiac events. We defined a cardiac event as an acute ischemic event or acute heart failure (Appendix Table A3 ). Cumulative incidence estimates were derived to account for competing risk of death. To compare differences in incidence by CVD-RFs, Cox regression was used to calculate time to event, from registration to cardiac event or censor (death or date of last contact), stratified by study and adjusted for baseline age, race, and prognostic risk score. Some patients experienced gaps in observation when Medicare coverage was discontinued temporarily (n = 35 with gaps of $ 3 months; gaps , 3 months were ignored to allow for administrative switching between plans). Participant time at risk in Cox models for cardiac event outcomes included only time under Medicare observation. As stated previously, Cox regression was performed separately for each CVD-RF. Additional analyses were performed to assess the impact of having multiple concurrent risk factors, and secondary analyses were performed separately by study type (adjuvant v advanced). In all analyses, P values were two-sided and were based on a Wald test statistic. P , .05 was considered significant. All tests were performed in SAS, Version 9.4 (SAS Institute, Cary, NC).
RESULTS
Of a total of 1,460 participants $ 66 years of age in the included trials, 842 participants were eligible for analyses of baseline cardiovascular conditions and survival outcomes and 736 patients were eligible for analyses of baseline cardiovascular conditions and cardiac event outcomes (Appendix Fig A1, online only) . Patient characteristics are listed in Table 1 . Among patients in both analyses, the median age was 70 years, and the median follow-up was 6 years. The majority of patients were non-Hispanic white. Hypertension was the most prevalent condition (73% in both cohorts), followed by hypercholesterolemia (57% in the survival cohort, 58% in the cardiac event cohort), and 87% of patients in each cohort had at least one CVD-RF.
Baseline Cardiovascular Risk Factors as Predictors of Survival
We observed no statistically significant association between any of the individual cardiovascular conditions and overall survival, except for hypercholesterolemia, which was associated with improved overall survival (hazard ratio [HR], 0.73; 95% CI, 0.57 to 0.93; P = .01), progression-free survival (HR, 0.80; 95% CI, 0.65 to 0.99; P = .04), and cancer-free survival (HR, 0.76; 95% CI, 0.57 to 1.00; P = .05; Table 2 ; Fig 1) . The association between hypercholesterolemia and better survival was stronger in advanced BC studies, with considerably improved overall survival (HR, 0.65; 95% CI, 0.48 to 0.88; P = .006), progression-free survival (HR, jco.org 0.68; 95% CI, 0.52 to 0.89; P = .005), and cancer-free survival (HR, 0.62; 95% CI, 0.45 to 0.85; P = .003). Among participants in adjuvant studies only, the presence of CAD was marginally associated with worse overall survival (HR, 1.53; 95% CI, 0.97 to 2.41; P = .07) and progression-free survival (HR, 1.46; 95% CI, 0.97 to 2.21; P = .07). We calculated the number of adverse CVDRFs on the basis of Cox regression results for overall survival across all studies. Adverse risk was defined as having diabetes, hypertension, CAD, obesity, or the absence of hypercholesterolemia. Because so few patients had fewer than four conditions, we combined four and five concurrent conditions into one category. With each additional risk factor, there was a trend of increased risk of death (HR, 1.23; 95% CI, 1.08 to 1.40; P = .002), worse progression-free survival (HR, 1.12; 95% CI, 1.00 to 1.25; P = .05), and marginally worse cancer-free survival (HR, 1.15; 95% CI, 0.99 to 1.34; P = .07). A sensitivity analysis was performed with hypercholesterolemia excluded as a risk factor, given its univariable association with better rather than worse survival; the results were of similar direction and magnitude, although not statistically significant (results not shown). There was no difference in overall survival between patients with versus without a Medicare linkage (HR, 0.94; 95% CI, 0.79 to 1.11; P = .45; Appendix Fig A2, online only).
Baseline Cardiovascular Risk Factors as Predictors of Cardiac Events
The proportion of patients who experienced cardiac events was much higher among patients with baseline CVD-RFs than among those without. The presence of CAD was associated with a more than two-fold increased risk of eventual cardiac event (HR, 2.65; 95% CI, 1.70 to 4.13; P , .001), and diabetes was associated with a two-fold increased risk of a cardiac event (HR, 2.00; 95% CI, 1.30 to 3.07; P = .002; Table 3 ). We stratified the analyses by study type and found that in adjuvant studies, there was a more than three-fold increased risk of cardiac events among participants with hypertension (HR, 3.20; 95% CI, 1.39 to 7.39; P = .006) or CAD (HR, 3.44; 95% CI, 2.04 to 5.80; P , .001). Hypercholesterolemia and obesity were not associated with increased risk of a cardiac event. There were no statistically significant associations between Abbreviations: CAD, coronary artery disease or ischemic heart disease. *Baseline prognostic risk score is explained in Appendix Table A4 . †Obesity at baseline is based on study questionnaires and at postbaseline is based on International Classification of Diseases (9th revision, clinical modification) codes in Appendix Table A2. any of the risk factors and cardiac events among participants in advanced studies only, except diabetes (HR, 2.37; 95% CI, 1.09 to 5.18; P = .03). We calculated the number of CVD-RFs on the basis of having diabetes, hypertension, CAD, obesity, or hypercholesterolemia. Because so few patients had fewer than four conditions, we combined four and five concurrent conditions into one category. A linear association between the number of concurrent risk factors and eventual cardiac event was observed (HR for each additional risk factor, 1.41; 95% CI, 1.17 to 1.69; P # .001; Table 3 ). The cumulative incidence of cardiac events by statistically significant baseline CVD-RFs for both adjuvant and advanced studies is shown in Figure 2 . A simple adverse risk model was derived by summing the number of statistically significant adverse cardiac factors from among the statistically significant factors in univariable analysis (diabetes, hypertension, and CAD), grouped by 0 to 1 versus 2 versus 3. The association between factor levels and development of cardiac events was even stronger for all patients (Table 3; Fig 2) . This linear relationship was also evident in the subset of adjuvant and advanced studies, respectively (Table 3 ; Fig 3) .
Although trends were similar, the number of adverse risk factors for cardiac events was not a statistically significant predictor of survival patterns (Table 2) . For both the analyses of survival outcomes and cardiac events outcomes, there was no association between number of CVD-RFs and treatment discontinuation (P = .63 and P = .70, respectively).
DISCUSSION
In this study of patients enrolled in five BC clinical trials, the presence of each additional CVD-RF was associated with worse overall and progression-free survival. CAD was independently associated with marginally worse overall survival and progression-free survival among participants in adjuvant studies, whereas hypercholesterolemia was actually associated with improved overall survival, particularly among patients with advanced disease. Similarly, the presence of each additional significant CVD-RF (diabetes, CAD, and hypertension) was associated with an increased risk of a subsequent cardiac event in all patients and when separately analyzed by adjuvant and advanced studies.
The proportion of death due to cardiovascular disease has been increasing among older women with BC. In a recent study of long-term survivors of adult-onset cancer, 28.8% of the study participants who had BC had a significantly higher risk of developing cardiovascular disease than their noncancer counterparts, and overall survival was significantly worse among patients with cancer with cardiovascular disease.
22 A large study of women older than 66 years of age with BC identified in the SEER database showed that cardiovascular disease, which was defined as congestive heart failure, myocardial infarction, peripheral vascular disease, or cerebrovascular disease, was the leading cause of death Abbreviations: CAD, coronary artery disease or ischemic heart disease; HR, hazard ratio. *Cancer-specific death was defined as any death that occurred either within 180 days of registration or after disease progression. †HRs and P values are stratified by study identification and treatment arm, and adjusted for age (66 to 70/$ 70 years), race (black/other), and baseline prognostic risk (low/high). P values are two-sided and are based on a Wald test statistic.
‡Number of baseline cardiovascular risk factors is defined based on Cox regression results, for overall survival among all studies, as the number of concurrent factors: diabetes, hypertension, no hypercholesterolemia, CAD, or obesity.
§On the basis of the adverse risk model including the three factors that were statistically significantly associated with cardiac events (diabetes, hypertension, and CAD only).
jco.org in the study population and was the primary cause of death among older women with stage I and II cancers. 2 We also found that the number of baseline CVD-RFs was associated with worse overall survival, consistent with the current literature.
The association of CAD with worse overall survival and increased risk of cardiac events may have only been seen in adjuvant and not advanced studies for several reasons. First, patients with advanced cancer have a poor overall prognosis and short life plot of survival by baseline comorbidity status. BL, baseline; CAD, coronary artery disease or ischemic heart disease; CVD-RF, cardiovascular-disease risk factor. Abbreviations: CAD, coronary artery disease or ischemic heart disease; HR, hazard ratio. *HRs and P values are stratified by study identification and treatment arm, and adjusted for age (66 to 70/$ 70), race (black/other), and baseline prognostic risk (low/high). P values are two-sided and are based on a Wald test statistic.
†Includes diabetes, hypertension, hypercholesterolemia, CAD, and obesity. Because of small numbers of patients with many concurrent risk factors, patients with four or five factors are combined.
‡Includes only the risk factors that had a statistically significant association with cardiac events among the whole population of studies: diabetes, hypertension, and CAD. Patients with zero or one risk factor are combined.
expectancy and thus may be at greater risk for cancer-specific death than death due to cardiac events, which usually results from longterm cumulative risk related to comorbidities. Second, elderly patients are less adherent to their medications for chronic diseases after BC treatment, and decreased adherence to heart failure regimens can lead to cardiac events and mortality over time, which again may not have been captured in advanced studies. 23 Third, two of the five studies included in this study, both adjuvant studies, included doxorubicin in the treatment regimens. Patients who receive doxorubicin have a significantly increased risk of developing cardiomyopathy, congestive heart failure, and heart disease; elderly patients seem to be at greater risk for developing anthracyclinerelated cardiotoxicity, particularly incident congestive heart failure, than their younger counterparts.
9,24 As such, elderly patients are also at higher risk for experiencing cardiac events after receiving anthracycline-based chemotherapy, particularly if they had preexisting CVD-RFs. 25 Neither of the two advanced studies examined in the current study used anthracycline-based treatment regimens as the primary treatment.
Diabetes has been consistently associated with poorer overall survival among patients with BC, but the association with cancer-specific survival is less clear, with conflicting results in jco.org various studies. [26] [27] [28] The increased mortality seen in patients with diabetes has largely been attributed to an increased risk of cardiovascular events. Patients with diabetes present with later-stage disease at the time of BC diagnosis, may receive altered treatment regimens because of poorer baseline health, and may be at greater risk for experiencing treatment-related adverse effects. 27 However, the use of metformin in patients with diabetes may improve overall and cancer-specific survival, possibly by inhibiting cancer cell proliferation or contributing to improved chemotherapy response. 29 In our study, diabetes was not significantly associated with worse overall survival, but did contribute to increased risk of all-cause mortality in conjunction with other CVD-RFs and was associated with increased risk of cardiac events, suggesting that any association with increased mortality seen in the literature may indeed be largely due to increased risk of cardiovascular events.
The finding that hypercholesterolemia was actually associated with improved overall survival, particularly among patients with advanced BC, is interesting; there are various possible explanations for this finding. Statins are considered first-line therapy in the prevention of cardiovascular mortality in patients with hypercholesterolemia and have been associated with improved disease-free survival in patients with BC. 30 This association has also been seen in other cancers; a recent study of postdiagnosis statin use in patients with prostate cancer showed an association with decreased cancerspecific and all-cause mortality. 31 We were unable to assess which patients were receiving statin therapy in this analysis. Obesity is a significant risk factor for the development of BC, presentation at a later stage, and overall mortality among patients with BC, but contrary to this, the obesity paradox has been seen in various other cancers where increased BMI may actually be protective in later-stage disease against the wasting and cachexia effects of cancer.
32-34 Although no significant association was seen in our study between obesity and overall survival in advanced studies, a recent study of postmenopausal women with BC in endocrine therapy trials found that a mean increase in BMI of 0.3 kg/m 2 was associated with improved survival after 1 year. 35 A similar mechanism may be at play among late-stage patients with hypercholesterolemia in protection against sarcopenia, frailty, and wasting; obese women often have elevated levels of LDL cholesterol. The effect of hypercholesterolemia specifically in advanced BC has not been well studied; additional studies are warranted to clarify the relationship observed in our study.
There are several strengths to our study. Participants were required to adhere to uniform protocol-specific therapy, and the data were collected prospectively, enabling assessment of progression-free and cancer-free survival in addition to overall survival. These end points are rarely available in tumor registry analyses. Uniform access to protocol therapy also limits the confounding influence of access to cancer care. We were also able to examine the association of multiple important CVD-RFs with survival and cardiac events. We also acknowledge several limitations. Patients were required to be enrolled in Medicare to be included in this study; therefore, all analyzed patients were older than 66 years of age; given that elderly patients are often underrepresented in clinical trials, selection bias may limit the generalizability of the results. Importantly, however, older patients are those most at risk for cardiovascular events. We used ICD9 codes to identify patients with CVD-RFs, but there are circumstances in which patients' conditions may not be properly codified and thus subject to misclassification bias. All five SWOG studies mandated a Zubrod score of 0 to 2, specifying that patients needed to be at least ambulatory and capable of self-care as part of the inclusion criteria; therefore, patients with severe complications from their comorbidities and who may have been at higher cardiovascular event risk may not have been captured, also potentially limiting the generalizability of our results. Finally, specific cause-of-death data were not available, necessitating the use of documented progression as an indicator of cancer-specific deaths.
In conclusion, our study demonstrates significantly increased risk of all-cause mortality among patients with breast cancer and CAD, and shows a worsening of overall and progression-free survival with each additional cardiovascular risk factor. In addition, we show that even among women with advanced cancer, the number of significant cardiovascular risk factors is associated with overall survival and risk of a cardiac event. Because both early-stage patients and those with metastatic breast cancer live longer, care needs to be taken in monitoring cardiovascular risk factors, especially among those with multiple concurrent risk factors, to reduce the burden of death due to noncancer causes.
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